摘要
目的了解益生菌制剂(双歧三联杆菌活检胶囊)增加标准四联根除幽门螺旋杆菌(H.pylori)方案的临床疗效及其对根除H.pylori过程的不良反应的改善情况。方法对H.pylori阳性患者采用随机双盲试验,随机分为益生菌组:埃索美拉唑钠肠溶片20mg+果胶铋200mg(2次/d,餐前0.5h)+阿莫西林1 000mg+克拉霉素500mg(2次/d,餐后即服)+益生菌(培菲康,双歧三联杆菌活菌胶囊)420mg(3次/d,与抗生素间隔2h以上);150例患者纳入安慰剂组:标准四联(同上)+安慰剂,各方案疗程均为14d,治疗结束并所用药物停药后4周对患者进行13 C呼气试验(13 C-UBT)检查,了解H.pylori根除率,治疗期间第7、14、30天对患者进行随访观察了解不良反应情况。结果 ITT分析益生菌组H.pylori根除率为85.6%,安慰剂组为75.1%;PP分析益生菌组H.pylori根除率为87.4%,安慰剂组为76.7%;益生菌组较安慰剂组不良反应发生率下降。结论联合应用益生菌制剂可提高H.pylori根除率且对治疗过程中不良反应有明显改善作用。
Objective To explore the effects of a probiotic Bifid Triple Viable capsules in standard quadruple regime for eradication of H. pylori. Methods 300 patients with H. pylori infection were randomized to the Probiotic group or Placebo group （n= 150）. The Prohiotic group was given the standard quadruple ther- apy （esomeprazole, clarithromycin, amoxicillin and bismuth） and Bifid Triple Viable capsules, while the Placebo group accepted the same quadruple therapy and placebo; the course of treatment was 14 days. Four weeks after the end of the treatment, 13C-breath test was performed. Adverse reactions were recorded dur- ing the treatment. Results 287 patients completed the study, 145 in Probiotic group and 142 in Placebo group. PP analysis showed the eradication rate was 87.4%in Probiotic group and 76.7% in Placebo group （P〈0.05）, while ITT result showed that the eradication rate was 85. 6 % in Probiotic group and 75.1 % in Placebo group （P〈0.05）. The rate of advise effects in Probiotic group was lower than in Placebo group （P〈0.05）. Conclusion The use of this probiotic combined with standard eradication therapy can improve the eradication rate of H. pylori and reduce the rate of adverse effects.
出处
《中国微生态学杂志》
CAS
CSCD
2015年第10期1181-1183,共3页
Chinese Journal of Microecology
